Morgan Tevlin
Nurse Practitioner · Colorado Springs, CONPI 1538656491
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,848 of the $8,508 with a category attached, or 80.5%. 29 manufacturers reported payments, led by Medtronic at 24.7% of the total. 2025 is the largest year on record at $3,224, 4.7 times the $679 reported in 2021. Among nurse practitioner clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 311 payments — averaging $27.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- AbbVie$1K
- Johnson & Johnson$1K
- Gilead$763
- Sanofi$462
- Takeda Pharmaceuticals U.S.A., Inc.$369
- plus $3K from 23 others
What the payments were for
- Travel & lodging$1,33016%
- Food & beverage$6,84880%
- Education$3304%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 18 | $2,101 |
| AbbVie | 61 | $1,160 |
| Johnson & Johnson | 44 | $1,060 |
| Gilead | 36 | $763 |
| Sanofi | 18 | $462 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $369 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $367 |
| Ardelyx, Inc. | 12 | $320 |
| Lilly USA, LLC | 14 | $271 |
| Intercept Pharmaceuticals, Inc. | 10 | $261 |
| Bristol Myers Squibb | 12 | $213 |
| QOL Medical, LLC | 10 | $172 |
| Novo Nordisk | 1 | $120 |
| Madrigal Pharmaceuticals | 4 | $109 |
| Regeneron Healthcare Solutions, Inc. | 5 | $102 |
| Celltrion USA Inc. | 6 | $102 |
| Pfizer | 3 | $101 |
| Janssen Scientific Affairs, LLC | 1 | $98 |
| Redhill Biopharma Inc. | 3 | $57 |
| Ironwood Pharmaceuticals, Inc | 3 | $57 |
| Mylan Institutional Inc. | 2 | $50 |
| Amgen | 2 | $38 |
| Ferring Pharmaceuticals Inc. | 2 | $32 |
| Ipsen Biopharmaceuticals, Inc | 1 | $27 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Braintree Laboratories, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,508 in reported general payments places this provider in the 95th percentile of 1,384 nurse practitioner providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcalivaObeticholic Acid | 13 | $242,050 |
| XifaxanRifaximin | 28 | $91,739 |
| CreonLipase/Protease/Amylase | 38 | $89,745 |
| LinzessLinaclotide | 54 | $51,684 |
| ZenpepLipase/Protease/Amylase | 26 | $45,334 |
| IbsrelaTenapanor Hcl | 12 | $21,548 |
| Sucralfate | 74 | $9,044 |
| Ursodiol | 31 | $4,678 |
| Colestipol Hcl | 25 | $3,710 |
| Dexlansoprazole DrDexlansoprazole | 12 | $3,189 |
| Omeprazole | 190 | $2,904 |
| Pantoprazole Sodium | 124 | $1,273 |
| Famotidine | 31 | $859 |
| ConstuloseLactulose | 20 | $823 |
| Lactulose | 12 | $474 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Intercept Pharmaceuticals, Inc.Ocaliva | $261 | $242,05013 claims |
| AbbVieCreon, Linzess | $1,160 | $141,43092 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $367 | $91,73928 claims |
| Aimmune Therapeutics, Inc.Zenpep | $23 | $45,33426 claims |
| Ardelyx, Inc.Ibsrela | $320 | $21,54812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,384 nurse practitioner providers in Colorado.
Other nurse practitioner in Colorado Springs
- Deborah HinnenColorado Springs$388K
- Lisa KeithColorado Springs$52K
- Brianne WagnerColorado Springs$11K
- Jill SmothersColorado Springs$8K
- Tracey PutzColorado Springs$8K
- Chris SchabingerColorado Springs$7K
- Bridget CoyneColorado Springs$6K
- Anne ZobecColorado Springs$5K
- Kathryn BlairColorado Springs$5K
- Mary Burkhart-GordonColorado Springs$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.